Fidelity D & D Bancorp Inc. Has $315,000 Stock Position in Amgen Inc. (NASDAQ:AMGN)

Fidelity D & D Bancorp Inc. grew its position in Amgen Inc. (NASDAQ:AMGN) by 9.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 977 shares of the medical research company’s stock after acquiring an additional 87 shares during the quarter. Fidelity D & D Bancorp Inc.’s holdings in Amgen were worth $315,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of AMGN. Capital Performance Advisors LLP acquired a new stake in Amgen during the third quarter valued at approximately $25,000. Hershey Financial Advisers LLC bought a new position in shares of Amgen during the 2nd quarter worth approximately $30,000. Legacy Investment Solutions LLC acquired a new stake in Amgen in the 3rd quarter valued at $29,000. nVerses Capital LLC acquired a new stake in Amgen in the 2nd quarter valued at $31,000. Finally, Matrix Trust Co bought a new stake in Amgen in the third quarter valued at $36,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on AMGN shares. UBS Group cut their price objective on Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a report on Thursday, October 31st. Dbs Bank raised shares of Amgen to a “strong-buy” rating in a report on Monday, September 16th. Sanford C. Bernstein began coverage on shares of Amgen in a research report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price target on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 price objective on shares of Amgen in a report on Tuesday, November 12th. Finally, Robert W. Baird reissued an “underperform” rating and issued a $215.00 target price on shares of Amgen in a report on Wednesday, September 25th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $319.68.

Amgen Trading Down 0.6 %

AMGN traded down $1.66 during trading on Friday, reaching $272.40. 98,604 shares of the company’s stock were exchanged, compared to its average volume of 2,609,521. The company’s fifty day moving average price is $303.00 and its 200-day moving average price is $314.87. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The firm has a market capitalization of $146.42 billion, a PE ratio of 35.09, a P/E/G ratio of 2.91 and a beta of 0.55. Amgen Inc. has a fifty-two week low of $257.80 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same quarter in the prior year, the company posted $4.96 earnings per share. The firm’s revenue was up 23.2% on a year-over-year basis. As a group, equities analysts forecast that Amgen Inc. will post 19.53 EPS for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a dividend of $2.38 per share. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 annualized dividend and a yield of 3.49%. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.